Free tool
FAERS Monitor: Edarbi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 200796 or its brand name (Edarbi, Azilsartan Kamedoxomil). Reports on generic versions are filed under their own applications.
Reports
3,052
Serious
2,180
71% of reports
Hospitalization
1,145
Death reported
256
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea169
- hypertension165
- drug ineffective135
- dizziness132
- nausea131
- off label use115
- fatigue113
- headache106
- renal impairment100
- malaise99
- blood pressure increased97
- decreased appetite95
- hypotension87
- wrong technique in product usage process75
- vomiting73
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 26 |
| 2012 | 43 |
| 2013 | 68 |
| 2014 | 54 |
| 2015 | 75 |
| 2016 | 166 |
| 2017 | 220 |
| 2018 | 152 |
| 2019 | 168 |
| 2020 | 196 |
| 2021 | 233 |
| 2022 | 386 |
| 2023 | 381 |
| 2024 | 333 |
| 2025 | 355 |
| 2026 | 196 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,107 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| renal impairmentSignal | 100 | 8.2 | 6.8 | 628 |
| hypertensionSignal | 165 | 5.4 | 4.6 | 588 |
| blood pressure increasedSignal | 97 | 4.4 | 3.6 | 251 |
| hypotensionSignal | 87 | 3.0 | 2.4 | 114 |
| decreased appetiteSignal | 95 | 2.8 | 2.3 | 111 |
| wrong technique in product usage processSignal | 75 | 2.6 | 2.0 | 70 |
| dizziness | 132 | 1.8 | 1.5 | 49 |
| diarrhoea | 169 | 1.8 | 1.6 | 62 |
| malaise | 99 | 1.6 | 1.3 | 20 |
| headache | 106 | 1.2 | 1.0 | 2 |
| nausea | 131 | 1.1 | 1.0 | 2 |
| vomiting | 73 | 1.1 | 0.9 | 0 |
| fatigue | 113 | 1.0 | 0.8 | 0 |
| off label use | 115 | 0.9 | 0.8 | 1 |
| drug ineffective | 135 | 0.7 | 0.6 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.